ZA200204020B - Use of anti-CTLA-4-antibodies. - Google Patents

Use of anti-CTLA-4-antibodies.

Info

Publication number
ZA200204020B
ZA200204020B ZA200204020A ZA200204020A ZA200204020B ZA 200204020 B ZA200204020 B ZA 200204020B ZA 200204020 A ZA200204020 A ZA 200204020A ZA 200204020 A ZA200204020 A ZA 200204020A ZA 200204020 B ZA200204020 B ZA 200204020B
Authority
ZA
South Africa
Prior art keywords
ctla
antibodies
Prior art date
Application number
ZA200204020A
Other languages
English (en)
Inventor
Hanson Douglas Charles
Mueller Eileen Elliott
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200204020B publication Critical patent/ZA200204020B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200204020A 2001-05-23 2002-05-21 Use of anti-CTLA-4-antibodies. ZA200204020B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29304201P 2001-05-23 2001-05-23

Publications (1)

Publication Number Publication Date
ZA200204020B true ZA200204020B (en) 2003-11-21

Family

ID=23127385

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200204020A ZA200204020B (en) 2001-05-23 2002-05-21 Use of anti-CTLA-4-antibodies.

Country Status (14)

Country Link
US (1) US20030086930A1 (cs)
EP (1) EP1262193A1 (cs)
JP (1) JP2002371013A (cs)
KR (1) KR100531707B1 (cs)
CN (1) CN1404876A (cs)
AU (1) AU4242102A (cs)
CA (1) CA2382443A1 (cs)
CZ (1) CZ20021760A3 (cs)
HU (1) HUP0201737A2 (cs)
IL (1) IL149701A0 (cs)
MY (1) MY136095A (cs)
PL (1) PL354112A1 (cs)
SK (1) SK7242002A3 (cs)
ZA (1) ZA200204020B (cs)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
CN1652820A (zh) * 2002-04-12 2005-08-10 梅达雷克斯公司 使用ctla－4抗体的治疗方法
BRPI0314038B8 (pt) 2002-09-06 2021-05-25 Amgen Inc anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
CN104119439A (zh) * 2003-06-27 2014-10-29 艾默根佛蒙特有限公司 针对表皮生长因子受体的缺失突变体的抗体及其使用
EP1648510B1 (en) 2003-07-22 2013-06-19 Bayer Pharma Aktiengesellschaft Rg1 antibodies and uses thereof
AU2004266246A1 (en) 2003-08-14 2005-03-03 Dyax Corp. Endotheliase-2 ligands
EP1515505A1 (en) * 2003-09-12 2005-03-16 Siemens Aktiengesellschaft Reachability maintainance of a moving network based on temporary name identifiers
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
CA2560919A1 (en) * 2004-03-26 2005-10-06 Pfizer Products Inc. Uses of anti-ctla-4 antibodies
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
JP2008518902A (ja) * 2004-11-04 2008-06-05 ファイザー・プロダクツ・インク 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療
EP1871806A2 (en) 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC ANTI-MAdCAM ANTIBODY COMPOSITIONS
CA2602956A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Therapy of prostate cancer with ctla4 antibodies and hormonal therapy
US20090074787A1 (en) * 2005-03-23 2009-03-19 Pfizer, Inc., Pfizer Products, Inc. Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer
CA3151350A1 (en) * 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CA2611861C (en) 2005-06-08 2017-11-28 The Brigham And Women's Hospital, Inc. Methods and compositions for the treatment of persistent infections
CA2614320A1 (en) * 2005-07-07 2007-01-18 Coley Pharmaceutical Group, Inc. Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
US8110194B2 (en) 2005-12-07 2012-02-07 Medarex, Inc. CTLA-4 antibody dosage escalation regimens
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
JP2010534719A (ja) * 2007-07-27 2010-11-11 ファイザー・リミテッド 沈殿化による抗体精製方法
EP2205249B1 (en) 2007-09-28 2018-11-07 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
RU2373836C2 (ru) * 2007-12-18 2009-11-27 Федеральное государственное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова Федерального агентства по высокотехнологичной медицинской помощи" Способ оптимизации лечебной тактики при лимфоме ходжкина у детей и подростков
EP2962731A1 (en) * 2008-01-08 2016-01-06 Bristol-Myers Squibb Company Combination of ipilimumab and paclitaxel for the treatment of cancer
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
ES2629167T3 (es) * 2009-07-20 2017-08-07 Bristol-Myers Squibb Company Combinación de anticuerpo anti-CTLA4 con etopósido para el tratamiento sinérgico de enfermedades proliferativas
RU2421217C2 (ru) * 2009-09-03 2011-06-20 Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
EP2699598B1 (en) 2011-04-19 2019-03-06 Pfizer Inc Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
EP2714094B1 (en) 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
RS58964B1 (sr) 2012-03-13 2019-08-30 Hoffmann La Roche Kombinovana terapija za lečenje karcinoma jajnika
SI2844282T1 (sl) 2012-05-04 2019-08-30 Pfizer Inc. S prostato povezani antigeni in na cepljenju osnovan imunoterapevtski režim zdravljenja
DK2887959T3 (en) * 2012-08-23 2019-02-18 Agensys Inc ANTIBODY-PHARMACEUTICAL CONJUGATES (ADC) BINDING TO 158P1D7 PROTEINS
PL2925350T3 (pl) * 2012-12-03 2019-07-31 Bristol-Myers Squibb Company Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc
BR112016002614B8 (pt) 2013-08-08 2023-11-07 Hopitaux Paris Assist Publique Imunocitoquina e composição farmacêutica
SI3030262T1 (sl) 2013-08-08 2020-03-31 Cytune Pharma Kombiniran farmacevtski sestavek
EA037890B1 (ru) * 2013-10-18 2021-06-01 Ридженерон Фармасьютикалз, Инк. Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
EP3125938A4 (en) * 2014-03-31 2017-08-23 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
WO2015166640A1 (ja) * 2014-05-01 2015-11-05 株式会社アネロファーマ・サイエンス 異種ポリペプチド発現カセット
SMT202100116T1 (it) 2014-05-28 2021-05-07 Agenus Inc Anticorpi anti-gitr e metodi di utilizzo degli stessi
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
EP3204516B1 (en) 2014-10-06 2023-04-26 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CA3203273A1 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
EP3240801B1 (en) 2014-12-31 2021-01-20 Checkmate Pharmaceuticals, Inc. Combination tumor immunotherapy
CA2976446A1 (en) * 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
SG10201913500TA (en) 2015-05-29 2020-03-30 Agenus Inc Anti-ctla-4 antibodies and methods of use thereof
CN114853891A (zh) * 2015-07-22 2022-08-05 索伦托药业有限公司 与lag3结合的抗体治疗剂
JP2018523712A (ja) * 2015-08-18 2018-08-23 マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. 腫瘍に対する免疫調節療法を向上させる為のｖｄａｓの使用
CN116063542A (zh) 2015-12-02 2023-05-05 阿吉纳斯公司 抗体和其使用方法
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
EP3436066A1 (en) 2016-04-01 2019-02-06 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
EA039322B1 (ru) * 2016-04-15 2022-01-13 Эйдженус Инк. Антитела против ctla-4 и способы их применения
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
EP3505183B1 (en) * 2016-08-26 2022-03-30 Tetsuji Okuno Microvascular blood flow decreasing agent and use thereof
AU2017373945B2 (en) 2016-12-07 2025-01-23 Agenus Inc. Antibodies and methods of use thereof
MD3551660T2 (ro) 2016-12-07 2024-03-31 Agenus Inc Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
JP7490923B2 (ja) * 2018-02-02 2024-05-28 オンコシーフォー、インク． 免疫療法効果が向上し副作用が軽減した変異抗ｃｔｌａ－４抗体
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
WO2019179388A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel anti-ctla-4 antibody polypeptide
KR20210006905A (ko) 2018-04-09 2021-01-19 체크메이트 파마슈티칼스 바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
EP3820992A2 (en) 2018-07-11 2021-05-19 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN110092826B (zh) * 2019-02-28 2022-04-15 天津大学 CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
CN115803343A (zh) * 2020-05-26 2023-03-14 百奥泰生物制药股份有限公司 多特异性抗体及其应用
CN116113406B (zh) 2020-07-10 2025-08-29 密歇根大学董事会 Gas41抑制剂及其使用方法
EP4343004A3 (en) 2020-10-19 2024-09-11 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
WO2022223622A1 (en) 2021-04-20 2022-10-27 Institut Curie Compositions and methods for use in immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
HRP20010551B1 (hr) * 1998-12-23 2013-05-31 Pfizer Inc. Humana monoklonalna antitijela za ctla-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
KR20020047132A (ko) * 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules

Also Published As

Publication number Publication date
HU0201737D0 (cs) 2002-07-29
CZ20021760A3 (cs) 2003-05-14
EP1262193A1 (en) 2002-12-04
US20030086930A1 (en) 2003-05-08
MY136095A (en) 2008-08-29
KR20020090873A (ko) 2002-12-05
HUP0201737A2 (hu) 2003-02-28
CN1404876A (zh) 2003-03-26
PL354112A1 (en) 2002-12-02
IL149701A0 (en) 2002-11-10
AU4242102A (en) 2002-11-28
SK7242002A3 (en) 2003-07-01
JP2002371013A (ja) 2002-12-26
KR100531707B1 (ko) 2005-11-30
CA2382443A1 (en) 2002-11-23

Similar Documents

Publication Publication Date Title
ZA200204020B (en) Use of anti-CTLA-4-antibodies.
DE60235907D1 (en) Flächiges implantat
IL162266A (en) Substituted 2-thio-3,5-dicyano-4- phenyl-6-aminopyridines and the use of the same
MXPA03007834A (es) Uso de agonistas inversos de gabaa, en combinacion con agonistas parciales del receptor de nicotina, estrogenos, moduladores selectivos de estrogenos o vitamina e, para el tratamiento de transtornos cognitivos.
PL367308A1 (en) Novel use
MXPA03005286A (es) METODO Y APARATO PARA SUPERVISAR PULSACION DE INSTALACION DE ORDEnA.
GB0125088D0 (en) New use
GB0115181D0 (en) Novel use
GB0100762D0 (en) Novel use
DE60107296D1 (en) Kabelverstärkerverbindungsanordnung
HUP0500734A3 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones
GB0104554D0 (en) New uses
MXPA03007888A (es) Compuestos para tratamiento y prevencion de ulcera gastrica inducida por medicamentos.
MXPA03006970A (es) Nuevo uso de iloperidona.
GB0106031D0 (en) Use
GB0119920D0 (en) New use
ZA200306611B (en) New use.
GB0102482D0 (en) Use
GB0108115D0 (en) Use
GB0103899D0 (en) Use
GB0103892D0 (en) Use
GB0126186D0 (en) Use
CA93647S (en) Fauteuil
GB0118919D0 (en) Novel use
GB0100852D0 (en) Novel use